Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees.  The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Incyte Corp. adalah perusahaan biopharmaceutical yang bergerak dalam penemuan, pengembangan, dan komersialisasi terapi proprietari. Perusahaan ini berkantor pusat di Wilmington, Delaware dan saat ini mempekerjakan 2.844 karyawan penuh waktu. Perusahaan ini beroperasi di dua area terapeutik. Salah satu area terapeutik adalah Hematologi/Onkologi, yang mencakup Neoplasma Mieloproliferatif dan Penyakit Graft-Versus-Host, serta tumor padat dan keganasan hematologis. Area terapeutik lainnya adalah Inflamasi dan Autoimunitas, yang mencakup waralaba komersial Dermatologinya. Waralaba hematologi dan onkologi perusahaan terdiri dari enam produk, yaitu JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), dan ZYNYZ (retifanlimab-dlwr), serta berbagai program pengembangan klinis. Saluran pengembangan perusahaan juga mencakup dua antagonis molekul kecil pertama di kelasnya terhadap reseptor terkait-Mas (MRGPRX2) dan INCB000547, sebuah antagonis MRGPRX4 oral.

Incyte Stock

About Incyte

Key Statistics

Insights